Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis (ABC-STOP)

The purpose of this study is to determine whether etanercept can be withdrawn successfully (i.e. no occurrence of flares) in juvenile idiopathic arthritis (JIA) patients in whom disease remission is reached. Goals: to investigate in a randomized controlled trial: which proportion of JIA patients in remission can successfully discontinue etanercept compared to JIA patients in remission who continue etanercept; if time in remission on etanercept is an important factor in retaining remission after discontinuation of etanercept. to investigate in alle JIA patients who discontinue etanercept (including the control group): predicting factors (patient or disease characteristics, including time in remission, and MRP8/MRP14) for successfully discontinuation of etanercept; the disease course after discontinuation of etanercept (time to flare) and the effect of restarting etanercept after flaring.

Juvenile Idiopathic Arthritis (JIA) is the most common cause of chronic arthritis in children. Etanercept has proven to be an effective treatment for JIA. Considering the risk of occurrence of long-term side-effects and to prevent the burden of the weekly injections and costs, it is a logical step to discontinue etanercept after reaching remission (no disease activity for at least six months). Especially since there are concerns about the long-term effect of suppressing the immune system with etanercept. However, little is known about if successful discontinuation is possible or when to stop. Risk is that the disease might flare (reactivate) again. For this study, JIA patients in remission will be selected from the ABC-register (an observational study including all Dutch JIA patients who use etanercept). Eligible patients will be randomized to stop etanercept or continue it for another 9 months. Patients are followed with standard visits evaluating disease activity until 12 months after discontinuation of etanercept. In case of a disease flare etanercept therapy will be reintroduced immediately and the patient will be treated according to the insight of their treating physician. Expected is that JIA patients who were in remission for more than 12 months before discontinuation have a better chance to retain remission.

Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.

Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.

To evaluate if the flare-rate is different between the 2 arms (continuation and discontinuation of etanercept).

To evaluate between the 2 arms (continuation and discontinuation of etanercept) if time in remission on etanercept is an important factor in retaining remission after discontinuation of etanercept.

Evaluation of predictors (patient or disease characteristics, including time in remission, and MRP8/MRP14) for successful discontinuation of etanercept in all JIA patient who discontinue etanercept.

After a flare (exacerbation) occurs: evaluation of time to flare and the effect of restarting etanercept after flaring.

Inclusion Criteria: Diagnosis of Juvenile Idiopathic Arthritis (all subtypes) by the International League of Associations of Rheumatology (ILAR) criteria On etanercept therapy No MTX or low dose MTX (maximum 10 mg/m2) 3 or more months in remission according to the criteria of Wallace (i.e. 9 or more months of inactive disease) Age ≥4 and <18 years at start of study Written informed consent from parents and patients 12 years and over Exclusion Criteria: Systemic corticosteroids (up to 9 months prior to inclusion) Intra-articular corticosteroids (up to 6 months prior to inclusion) Synthetic DMARDs besides low dose MTX (up to 9 months prior to inclusion) Biologic DMARDs besides etanercept (up to 9 months prior to inclusion)